ABSTRACT
Histone deacetylase 3 (HDAC3) plays an important role in chromatin remodeling, which in turn regulates gene transcription, so HDAC3 is involved in the pathophysiology of various diseases through epigenetic regulation. Organ ischemia-reperfusion injury (I R I) is a pathophysiological process that leads to the development of a variety of diseases such as delayed neuronal necrosis, irreversible shock, myocardial infarction, acute organ failure and organ transplant rejection. In this paper we review the pathophysiological function of HDAC3 and its role in the development of IRI in human parenchymal organs, and also explore the therapeutic value of HDAC3 in IRI.
ABSTRACT
Acute lung injury ( ALI) and its most extreme form a-cute respiratory distress syndrome ( ARDS) are lung diseases with high morbidity and mortality. There is no effective therapeutic intervention until now for its complicated pathophysiologi-cal processes and sophisticated regulatory mechanism. Histone deacetylases (HDACs) are a family of proteins with deacetylase activity. Studies have shown that HDACs are involved in the pathophysiological processes of ALI/ARDS, including inflammatory responses,endothelial permeability,oxidative stresses,alveolar fluid clearance and lung tissue repairment. Simultaneously, the use of HDACs inhibitors (HDACIs) can interfere with ALI/ ARDS progression. In this review we describe and summarize the pathophysiological processes and the underlying mechanisms in ALI/ARDS regulated by HDACs and HDACIs in detail, in order to provide the basis for the clinical application of HDACs-targe- ted agents and indicate directions for future study.
ABSTRACT
As a pulmonary complication of diabetes, diabetic pulmonary fibrosis has gradually entered people's sight, but its mechanism is still poorly understood.This is the first systematic review of the mechanisms of autonomic neuropathy, pulmonary microangiopathy, accumulation of advanced glycosylation end products, oxidative stress, inflammation, epithelial-mesenchy- mal transition and endothelial-mesenchymal transition, cell se¬nescence and I)NA damage, etc.in diabetic pulmonary fibrosis.which aims to provide inquiring ideas for exploring the specific molecule mechanism and a reference for the development of ther¬apeutic drugs for diabetic pulmonary fibrosis.,,,,.